Richard Guy

2025 Opening Day full velvet buck

ARTICLE | Emerging Company Profile San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue By Richard Guy, Biopharma Analyst Switch Therapeutics is designing siRNAs that remain inactive until turned on inside cells containing a specific biomarker, allowing the company to selectively target cell types of interest within a tissue, without relying on surface proteins.

ARTICLE | Emerging Company Profile Company applying small molecule optimization techniques to peptides with a robotic synthesis platform By Richard Guy, Biopharma Analyst Backed with a $32 million series A round, Unnatural Products is the latest macrocycle company to spin out of Scott Lokey’s lab. The company’s empirical approach to macrocycle design, which entails synthesizing libraries of circular peptides using a bespoke robotic platform, has won it partnerships with Bridgebio and Merck.